Trial reportEuropean journal of nuclear medicine and molecular imaging2021
A microdose clinical trial to evaluate [
Trial report in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05004285 (A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi Center, Non-randomized, Open, Phase 3 Study to Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis in Prostate Cancer Risk Groups
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [Korean journal of radiology · 2024Article
- Comparison of the Effects of DOTA and NOTA Chelators onDiagnostics (Basel, Switzerland) · 2023Article
- Multi-timepoint imaging with PSMA-targeted [Annals of nuclear medicine · 2023Article
- Irreversible electroporation for prostate cancer using PSMA PET-CT.Prostate international · 2023Article
- Article
- Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.Nuclear medicine and molecular imaging · 2022Review
- A Brief History of Nuclear Medicine Physics, Instrumentation, and Data Sciences in Korea.Nuclear medicine and molecular imaging · 2021Review
- KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future.Nuclear medicine and molecular imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the biodistribution of [
methodsPET was performed for five healthy controls and 10 patients with prostate cancer at 0, 10, 30, 70, and 120 mins after injecting 370 MBq of [
resultsThe SUV
conclusionWe identified a novel PSMA-targeted PET ligand, [
trial registrationKCT0003924 registered at https://cris.nih.go.kr/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.